Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies.

Joubert B, Belbezier A, Haesebaert J, Rheims S, Ducray F, Picard G, Rogemond V, Psimaras D, Berzero G, Desestret V, Honnorat J.

J Neurol. 2020 Mar 28. doi: 10.1007/s00415-020-09807-2. [Epub ahead of print]

PMID:
32221776
2.

Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies.

Simard C, Vogrig A, Joubert B, Muñiz-Castrillo S, Picard G, Rogemond V, Ducray F, Berzero G, Psimaras D, Antoine JC, Desestret V, Honnorat J.

Neurol Neuroimmunol Neuroinflamm. 2020 Mar 13;7(3). pii: e699. doi: 10.1212/NXI.0000000000000699. Print 2020 May.

3.

Avoiding New Biopsies by Identification of IDH1 and TERT Promoter Mutation in Nondiagnostic Biopsies From Glioma Patients.

Barritault M, Picart T, Poncet D, Fenouil T, d'Hombres A, Gabut M, Guyotat J, Jouanneau E, Ameli R, Joubert B, Streichenberger N, Vasiljevic A, Honnorat J, Meyronet D, Ducray F.

Neurosurgery. 2020 Feb 28. pii: nyaa025. doi: 10.1093/neuros/nyaa025. [Epub ahead of print]

PMID:
32107549
4.

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.

Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre JY, Figarella-Branger D; POLA Network.

Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124.

PMID:
31832685
5.

The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.

Grandin N, Pereira B, Cohen C, Billard P, Dehais C, Carpentier C, Idbaih A, Bielle F, Ducray F, Figarella-Branger D, Delattre JY, Sanson M, Lomonte P, Poncet D, Verrelle P, Charbonneau M; POLA network.

Acta Neuropathol Commun. 2019 Nov 9;7(1):175. doi: 10.1186/s40478-019-0833-0.

6.

Letter to the Editor.

Meyronet D, Ducray F.

Neuro Oncol. 2019 Nov 4;21(11):1482. doi: 10.1093/neuonc/noz161. No abstract available.

PMID:
31648295
7.

Multinodular and Vacuolating Posterior Fossa Lesions of Unknown Significance.

Lecler A, Bailleux J, Carsin B, Adle-Biassette H, Baloglu S, Bogey C, Bonneville F, Calvier E, Comby PO, Cottier JP, Cotton F, Deschamps R, Diard-Detoeuf C, Ducray F, Duron L, Drissi C, Elmaleh M, Farras J, Garcia JA, Gerardin E, Grand S, Jianu DC, Kremer S, Magne N, Mejdoubi M, Moulignier A, Ollivier M, Nagi S, Rodallec M, Sadik JC, Shor N, Tourdias T, Vandendries C, Broquet V, Savatovsky J; ENIGMA Investigation Group (EuropeaN Interdisciplinary Group for MVNT Analysis).

AJNR Am J Neuroradiol. 2019 Oct;40(10):1689-1694. doi: 10.3174/ajnr.A6223. Epub 2019 Sep 26.

PMID:
31558497
8.

Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.

Vogrig A, Fouret M, Joubert B, Picard G, Rogemond V, Pinto AL, Muñiz-Castrillo S, Roger M, Raimbourg J, Dayen C, Grignou L, Pallix-Guyot M, Lannoy J, Ducray F, Desestret V, Psimaras D, Honnorat J.

Neurol Neuroimmunol Neuroinflamm. 2019 Aug 7;6(6). pii: e604. doi: 10.1212/NXI.0000000000000604. Print 2019 Nov.

9.

Charcot-Marie-Tooth (CMT)-like polyneuropathy revealing neurofibromatosis type 2: A case report and review of the literature.

Pegat A, Ducray F, Jeannin-Mayer S, Jouanneau E, Pinson S, Petiot P.

Rev Neurol (Paris). 2019 Sep - Oct;175(7-8):486-489. doi: 10.1016/j.neurol.2018.10.011. Epub 2019 Jun 17. No abstract available.

PMID:
31221421
10.

Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.

Bani-Sadr A, Berner LP, Barritault M, Chamard L, Bidet CM, Eker OF, Hermier M, Guyotat J, Jouanneau E, Meyronet D, Gouttard S, D'Hombres A, Iziquierdo C, Honnorat J, Berthezène Y, Ducray F.

Rev Neurol (Paris). 2019 Oct;175(9):534-543. doi: 10.1016/j.neurol.2019.01.400. Epub 2019 Jun 14.

PMID:
31208813
11.

A Multiplex Quantitative Reverse Transcription Polymerase Chain Reaction Assay for the Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pilocytic Astrocytomas.

Bret D, Chappuis V, Poncet D, Ducray F, Silva K, Mion F, Vasiljevic A, Ferraro-Peyret C, Mottolese C, Leblond P, Gabut M, Frappaz D, Streichenberger N, Meyronet D, Bringuier PP, Barritault M.

Mol Diagn Ther. 2019 Aug;23(4):537-545. doi: 10.1007/s40291-019-00403-3.

PMID:
31087282
12.

Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age.

Castet F, Alanya E, Vidal N, Izquierdo C, Mesia C, Ducray F, Gil-Gil M, Bruna J.

J Neurooncol. 2019 Jul;143(3):515-523. doi: 10.1007/s11060-019-03183-2. Epub 2019 May 3.

PMID:
31054099
13.

Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the Literature.

Garnier L, Ducray F, Verlut C, Mihai MI, Cattin F, Petit A, Curtit E.

Front Oncol. 2019 Mar 26;9:177. doi: 10.3389/fonc.2019.00177. eCollection 2019.

14.

Simultaneous occurrence of giant cell arteritis and cerebral amyloid angiopathy.

Fouret M, Jamilloux Y, Szathmari A, Vasiljevic A, Meyronet D, Ducray F, Seve P.

Rheumatology (Oxford). 2019 Aug 1;58(8):1503-1505. doi: 10.1093/rheumatology/kez099. No abstract available.

PMID:
30927437
15.

Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study.

Ursu R, Thomas L, Psimaras D, Chinot O, Le Rhun E, Ricard D, Charissoux M, Cuzzubbo S, Sejalon F, Quillien V, Hoang-Xuan K, Ducray F, Portal JJ, Tibi A, Mandonnet E, Levy-Piedbois C, Vicaut E, Carpentier AF.

Eur J Cancer. 2019 Mar;109:129-136. doi: 10.1016/j.ejca.2018.12.025. Epub 2019 Feb 1.

PMID:
30716716
16.

The molecular landscape of glioma in patients with Neurofibromatosis 1.

D'Angelo F, Ceccarelli M, Tala, Garofano L, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras CE, McCutcheon I, Nam DH, Ronchi S, Saletti V, Seizeur R, Slopis J, Suñol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss DE, Kim SK, Meyronet D, Mokhtari K, Salvador H, Bhat KP, Eoli M, Sanson M, Lasorella A, Iavarone A.

Nat Med. 2019 Jan;25(1):176-187. doi: 10.1038/s41591-018-0263-8. Epub 2018 Dec 10.

17.

Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome.

Vogrig A, Joubert B, Maureille A, Thomas L, Bernard E, Streichenberger N, Cotton F, Ducray F, Honnorat J.

J Neurol. 2019 Feb;266(2):398-410. doi: 10.1007/s00415-018-9143-x. Epub 2018 Nov 29.

PMID:
30498914
18.

Stroke-like events after brain radiotherapy: a large series with long-term follow-up.

Di Stefano AL, Berzero G, Ducray F, Eoli M, Pichiecchio A, Farina LM, Cuccarini V, Brunelli MC, Diamanti L, Condette Auliac S, Salmaggi A, Silvani A, Giometto B, Pace A, Vidiri A, Bourdain F, Bastianello S, Ceroni M, Marchioni E.

Eur J Neurol. 2019 Apr;26(4):639-650. doi: 10.1111/ene.13870. Epub 2019 Jan 10.

PMID:
30471162
19.

Isolated seizures are a common early feature of paraneoplastic anti-GABAB receptor encephalitis.

Maureille A, Fenouil T, Joubert B, Picard G, Rogemond V, Pinto AL, Thomas L, Ducray F, Quadrio I, Psimaras D, Berzero G, Antoine JC, Desestret V, Honnorat J.

J Neurol. 2019 Jan;266(1):195-206. doi: 10.1007/s00415-018-9132-0. Epub 2018 Nov 20.

PMID:
30460450
20.

Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.

Izquierdo C, Barritault M, Poncet D, Cartalat S, Joubert B, Bruna J, Jouanneau E, Guyotat J, Vasiljevic A, Fenouil T, Berthezène Y, Honnorat J, Meyronet D, Ducray F.

Neurosurgery. 2019 Sep 1;85(3):E448-E456. doi: 10.1093/neuros/nyy513.

PMID:
30407589
21.

Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome.

Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA network.

Acta Neuropathol Commun. 2018 Sep 7;6(1):89. doi: 10.1186/s40478-018-0594-1.

22.

Molecular classification of adult gliomas: recent advances and future perspectives.

Barritault M, Meyronet D, Ducray F.

Curr Opin Oncol. 2018 Nov;30(6):375-382. doi: 10.1097/CCO.0000000000000482. Review.

PMID:
30148717
23.

Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma.

Rosenberg S, Ducray F, Alentorn A, Dehais C, Elarouci N, Kamoun A, Marie Y, Tanguy ML, De Reynies A, Mokhtari K, Figarella-Branger D, Delattre JY, Idbaih A; POLA Network.

Oncologist. 2018 Dec;23(12):1500-1510. doi: 10.1634/theoncologist.2017-0495. Epub 2018 Jul 17.

24.

Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies.

Bost C, Chanson E, Picard G, Meyronet D, Mayeur ME, Ducray F, Rogemond V, Psimaras D, Antoine JC, Delattre JY, Desestret V, Honnorat J.

J Neurol. 2018 Oct;265(10):2190-2200. doi: 10.1007/s00415-018-8970-0. Epub 2018 Jul 12.

PMID:
30003358
25.

Returning to work after multimodal treatment in glioblastoma patients.

Starnoni D, Berthiller J, Idriceanu TM, Meyronet D, d'Hombres A, Ducray F, Guyotat J.

Neurosurg Focus. 2018 Jun;44(6):E17. doi: 10.3171/2018.3.FOCUS1819.

PMID:
29852767
26.

Motor neuron disease of paraneoplastic origin: a rare but treatable condition.

Mélé N, Berzero G, Maisonobe T, Salachas F, Nicolas G, Weiss N, Beaudonnet G, Ducray F, Psimaras D, Lenglet T.

J Neurol. 2018 Jul;265(7):1590-1599. doi: 10.1007/s00415-018-8881-0. Epub 2018 May 3. Review.

PMID:
29725842
27.

IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas.

Appay R, Tabouret E, Macagno N, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA Network.

Neuro Oncol. 2018 Apr 9;20(5):716-718. doi: 10.1093/neuonc/noy014. No abstract available.

28.

Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy.

Bronnimann C, Izquierdo C, Cartalat S, Thomas L, Joubert B, Delpech L, Barritault M, Meyronet D, Honnorat J, Ducray F.

J Neurooncol. 2018 May;138(1):141-145. doi: 10.1007/s11060-018-2780-1. Epub 2018 Jan 31.

PMID:
29388033
29.

Glioblastoma as differential diagnosis of autoimmune encephalitis.

Vogrig A, Joubert B, Ducray F, Thomas L, Izquierdo C, Decaestecker K, Martinaud O, Gerardin E, Grand S, Honnorat J.

J Neurol. 2018 Mar;265(3):669-677. doi: 10.1007/s00415-018-8767-1. Epub 2018 Jan 30.

PMID:
29383516
30.

Characteristics of cerebellar glioblastomas in adults.

Picart T, Barritault M, Berthillier J, Meyronet D, Vasiljevic A, Frappaz D, Honnorat J, Jouanneau E, Poncet D, Ducray F, Guyotat J.

J Neurooncol. 2018 Feb;136(3):555-563. doi: 10.1007/s11060-017-2682-7. Epub 2017 Dec 1.

PMID:
29196927
31.

Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.

Izquierdo C, Alentorn A, Idbaih A, Simó M, Kaloshi G, Ricard D, Barritault M, Meyronet D, Bruna J, Honnorat J, Delattre JY, Ducray F.

J Neurooncol. 2018 Feb;136(3):533-539. doi: 10.1007/s11060-017-2677-4. Epub 2017 Nov 15.

PMID:
29143276
32.

Intravascular large B-cell lymphoma mimicking cerebral amyloid angiopathy-related inflammation.

Leclercq L, Mechtouff L, Hermier M, Cho TH, Nighoghossian N, Ducray F.

Rev Neurol (Paris). 2018 Apr;174(4):265-266. doi: 10.1016/j.neurol.2017.06.023. Epub 2017 Nov 7. No abstract available.

PMID:
29126561
33.

Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies.

Berzero G, Karantoni E, Dehais C, Ducray F, Thomas L, Picard G, Rogemond V, Candelier G, Camdessanché JP, Antoine JC, De Seze J, Liou-Schischmanoff A, Honnorat J, Delattre JY, Psimaras D.

J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):789-792. doi: 10.1136/jnnp-2017-316904. Epub 2017 Oct 30. No abstract available.

34.

Anaplastic gliomas in adults: an update.

Izquierdo C, Joubert B, Ducray F.

Curr Opin Oncol. 2017 Nov;29(6):434-442. doi: 10.1097/CCO.0000000000000409. Review.

PMID:
28901965
35.

Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.

Quillien V, Lavenu A, Ducray F, Meyronet D, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D.

Cancer Biomark. 2017 Dec 6;20(4):435-441. doi: 10.3233/CBM-170191.

36.

Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis.

Joubert B, Gobert F, Thomas L, Saint-Martin M, Desestret V, Convers P, Rogemond V, Picard G, Ducray F, Psimaras D, Antoine JC, Delattre JY, Honnorat J.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 14;4(4):e371. doi: 10.1212/NXI.0000000000000371. eCollection 2017 Jul.

37.

Characteristics of H3 K27M-mutant gliomas in adults.

Meyronet D, Esteban-Mader M, Bonnet C, Joly MO, Uro-Coste E, Amiel-Benouaich A, Forest F, Rousselot-Denis C, Burel-Vandenbos F, Bourg V, Guyotat J, Fenouil T, Jouvet A, Honnorat J, Ducray F.

Neuro Oncol. 2017 Aug 1;19(8):1127-1134. doi: 10.1093/neuonc/now274.

38.

Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies.

Do LD, Chanson E, Desestret V, Joubert B, Ducray F, Brugière S, Couté Y, Formaglio M, Rogemond V, Thomas-Antérion C, Borrega L, Laurens B, Tison F, Curot J, De Brouker T, Lebrun-Frenay C, Delattre JY, Antoine JC, Honnorat J.

Neurology. 2017 Feb 7;88(6):514-524. doi: 10.1212/WNL.0000000000003586. Epub 2017 Jan 6.

PMID:
28062719
39.

Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.

Fossard G, Ferlay C, Nicolas-Virelizier E, Rey P, Ducray F, Jouanneau E, Faurie P, Belhabri A, Sunyack MP, Chassagne-Clément C, Thiesse P, Sebban C, Biron P, Blay JY, Ghesquières H.

Eur J Cancer. 2017 Feb;72:12-19. doi: 10.1016/j.ejca.2016.10.036. Epub 2016 Dec 22.

PMID:
28012348
40.

Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.

Ollier E, Mazzocco P, Ricard D, Kaloshi G, Idbaih A, Alentorn A, Psimaras D, Honnorat J, Delattre JY, Grenier E, Ducray F, Samson A.

Fundam Clin Pharmacol. 2017 Jun;31(3):347-358. doi: 10.1111/fcp.12259. Epub 2017 Jan 24.

PMID:
27933657
41.

Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas.

Bielle F, Ducray F, Mokhtari K, Dehais C, Adle-Biassette H, Carpentier C, Chanut A, Polivka M, Poggioli S, Rosenberg S, Giry M, Marie Y, Duyckaerts C, Sanson M, Figarella-Branger D, Idbaih A; Pola Network.

Brain Pathol. 2017 Sep;27(5):567-579. doi: 10.1111/bpa.12434. Epub 2016 Oct 28.

PMID:
27543943
42.

Neuroleptic intolerance in patients with anti-NMDAR encephalitis.

Lejuste F, Thomas L, Picard G, Desestret V, Ducray F, Rogemond V, Psimaras D, Antoine JC, Delattre JY, Groc L, Leboyer M, Honnorat J.

Neurol Neuroimmunol Neuroinflamm. 2016 Aug 29;3(5):e280. doi: 10.1212/NXI.0000000000000280. eCollection 2016 Oct.

43.

Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.

Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre JY, Figarella-Branger D; For POLA Network.

Acta Neuropathol. 2016 Oct;132(4):625-34. doi: 10.1007/s00401-016-1611-8. Epub 2016 Aug 29.

PMID:
27573687
44.

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.

Quillien V, Lavenu A, Ducray F, Joly MO, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D.

Oncotarget. 2016 Sep 20;7(38):61916-61929. doi: 10.18632/oncotarget.11322.

45.

Characterization of a Subtype of Autoimmune Encephalitis With Anti-Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures.

Joubert B, Saint-Martin M, Noraz N, Picard G, Rogemond V, Ducray F, Desestret V, Psimaras D, Delattre JY, Antoine JC, Honnorat J.

JAMA Neurol. 2016 Sep 1;73(9):1115-24. doi: 10.1001/jamaneurol.2016.1585.

PMID:
27428927
46.

Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.

Paquette B, Vernerey D, Chauffert B, Dabakuyo S, Feuvret L, Taillandier L, Frappaz D, Taillia H, Schott R, Ducray F, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O, Anota A, Bonnetain F.

Cancer Med. 2016 Aug;5(8):1753-64. doi: 10.1002/cam4.734. Epub 2016 Jun 1.

47.

The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma.

Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X.

Neuro Oncol. 2016 Aug;18(8):1129-36. doi: 10.1093/neuonc/now102. Epub 2016 May 13.

48.

Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas.

Figarella-Branger D, Mokhtari K, Dehais C, Carpentier C, Colin C, Jouvet A, Uro-Coste E, Forest F, Maurage CA, Vignaud JM, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Loussouarn D, Lacroix C, Rigau V, Laquerrière A, Vandenbos F, Michalak S, Sevestre H, Peoch M, Labrousse F, Christov C, Kemeny JL, Chenard MP, Chiforeanu D, Ducray F, Idbaih A, Delattre JY; POLA Network.

Neuro Oncol. 2016 Jun;18(6):888-90. doi: 10.1093/neuonc/now085. No abstract available.

49.

Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas.

Kamoun A, Idbaih A, Dehais C, Elarouci N, Carpentier C, Letouzé E, Colin C, Mokhtari K, Jouvet A, Uro-Coste E, Martin-Duverneuil N, Sanson M, Delattre JY, Figarella-Branger D, de Reyniès A, Ducray F; POLA network.

Nat Commun. 2016 Apr 19;7:11263. doi: 10.1038/ncomms11263.

50.

Characteristics of gliomas in patients with somatic IDH mosaicism.

Bonnet C, Thomas L, Psimaras D, Bielle F, Vauléon E, Loiseau H, Cartalat-Carel S, Meyronet D, Dehais C, Honnorat J, Sanson M, Ducray F.

Acta Neuropathol Commun. 2016 Mar 31;4:31. doi: 10.1186/s40478-016-0302-y.

Supplemental Content

Loading ...
Support Center